"Data show that FcgammaRIIa and FcgammaRIIIa polymorphisms are not useful as molecular markers for outcome in mCRC patients and KRAS status and skin toxicity are the only reliable biomarkers to identify patients that would benefit from anti-EGFR therapy."xsd:string